Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116774 | 1.00 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Fumaric Acid SCHEMBL9085199 | 0.89 | KDM4E (0.43) | CHRNA7ALDH1A1LMNATDP1KDM4E | |
| SCHEMBL8070733 | 0.87 | CHRNB2 (0.46) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL24154837 | 0.82 | KDM4E (0.42) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL24155088 | 0.79 | TRPV6 (0.35) | — | |
| SCHEMBL8488992 | 0.77 | CHRNB2 (0.46) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL24154692 | 0.75 | CHRNB2 (0.49) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8071268 | 0.75 | TSHR (0.46) | ALDH1A1MAPTKDM4ECYP3A4TSHR | |
| SCHEMBL30116744 | 0.75 | TSHR (0.46) | ALDH1A1MAPTKDM4ECYP3A4TSHR | |
| SCHEMBL8077458 | 0.71 | CYP2A6 (0.40) | ALDH1A1CYP2A6KDM4ECYP3A4THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5583140-A | ADMINISTERING 2-AZABICYCLO(2.2.2)OCT-5-ENE DERIVATIVES TO TREAT NEURODEGENERATIVE DISORDERS SUCH AS SENILE DEMENTIA OF ALZHEIMER'S TYPE | TARGACEPT, INC. A CORP. OF DE, | 1996-12-10 | — | — | US | claimed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| EP-4172156-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | Philip Morris Products S.A. (CH) | 2023-05-03 | — | — | EP | disclosed |
| CN-115698002-A | Compositions and methods for parasite control | 菲利普莫里斯生产公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021260029-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260029-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2021-12-30 | — | — | WO | disclosed |
| US-6100269-A | ADMINISTERING TO PATIENT NICOTINIC RECEPTOR AGONISTIC DERIVATIVES OF 3-(PYRIDYL OR PYRIMIDYL)-2-AZABICYCLO(2.2.1) HEPTANE OR 2-AZABICYCLO(2.2.2.)OCTANE TO ELICIT NEUROTRANSMITTER SECRETION WITH REDUCED SIDE EFFECTS | BENCHERIF MEROUANE (US) | 2000-08-08 | — | — | US | disclosed |
| US-5583140-A | ADMINISTERING 2-AZABICYCLO(2.2.2)OCT-5-ENE DERIVATIVES TO TREAT NEURODEGENERATIVE DISORDERS SUCH AS SENILE DEMENTIA OF ALZHEIMER'S TYPE | TARGACEPT, INC. A CORP. OF DE, | 1996-12-10 | — | — | US | disclosed |
| WO-1996036637-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996036637-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | TRHDE, CUTA, PIGS | CHRNA7 3165/4885CHRNB2 4302/4885CHRNA4 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.